MARSEILLE, France, January 25, 2023--Innate Pharma announces HSR clearance regarding expansion of its collaboration with Sanofi on NK cell engagers
MARSEILLE, France, January 16, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123. The studies were conducted by Innate and Sanofi and published in Nature Biotechnology on January 12, 2023.
MARSEILLE, France, December 19, 2022--Sanofi and Innate Pharma expand collaboration for Natural Killer cell therapeutics in oncology